BIONET Therapeutics Corp. (TPEX:7808)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
52.10
-0.20 (-0.38%)
At close: Feb 11, 2026
Market Cap3.65B +13.3%
Revenue (ttm)105.67M +143.9%
Net Income-100.46M
EPS-1.49
Shares Out70.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,010
Average Volume44,761
Open51.60
Previous Close52.30
Day's Range51.60 - 52.10
52-Week Range37.70 - 66.30
Betan/a
RSI36.60
Earnings DateMar 20, 2026

About BIONET Therapeutics

BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney disease, acute wound healing, chronic wound healing of diabetic ulcers, and osteoarthritis. It also provides CRDMO services. The company was founded in 2022 and is based in Taipei, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2022
Employees 73
Stock Exchange Taipei Exchange
Ticker Symbol 7808
Full Company Profile

Financial Performance

In 2024, BIONET Therapeutics's revenue was 81.32 million, an increase of 1414.60% compared to the previous year's 5.37 million. Losses were -86.26 million, 131.0% more than in 2023.

Financial Statements